Brokerages Set Medexus Pharmaceuticals Inc. (TSE:MDP) Price Target at C$5.49

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and four have issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is C$5.49.

MDP has been the subject of several research reports. Stifel Nicolaus cut shares of Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price objective for the company from C$6.00 to C$3.45 in a research report on Friday, February 7th. Stifel Canada lowered shares of Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Ventum Financial raised their price target on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a “buy” rating in a report on Thursday, January 30th. Leede Financial raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, January 22nd. Finally, Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd.

Medexus Pharmaceuticals Stock Performance

Shares of TSE:MDP opened at C$2.47 on Wednesday. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$5.56. The firm has a market cap of C$55.30 million, a PE ratio of 11.81 and a beta of 1.96. The business has a fifty day moving average of C$3.40 and a 200-day moving average of C$2.92.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.